Post‐Marketing Requirements for Cancer Drugs Approved by the European Medicines Agency, 2004–2014
Open Access
- 23 June 2022
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 112 (4) , 846-852
Abstract
To address unresolved questions about drug safety and efficacy at the time of approval, the European Medicines Agency (EMA) may require that manufacturers conduct additional studies during the postmarketing period. As a growing proportion of new cancer drugs are approved on the basis of limited evidence of clinical benefit, timely completion of postmarketing requirements is important. We used publicly available regulatory documents to evaluate key characteristics of pivotal studies supporting EMA‐approved cancer drugs from 2004–2014 and assessed completion rates of postmarketing data collection requirements after a minimum of 5 years. From 2004–2014, 79% (45/57) of EMA‐approved cancer drugs had to fulfill postmarketing requirements. Pivotal trials supporting the approval of cancer drugs with postmarketing requirements were less likely to have randomized designs (41/61, 67% vs. 11/11, 100%), include an active comparator (20/61, 33% vs. 10/11, 91%), or measure overall survival as the primary study end point (18/61, 30% vs. 6/11, 55%) compared with pivotal trials for drugs without postmarketing requirements. Among 200 postmarketing requirements, almost half were designed to assess drug safety. After a minimum of 5 years, 60% (121/200) of requirements were completed, 10% (19/200) were ongoing, and 30% (60/200) were delayed. About half (40/75, 53%) of postmarketing requirements for new clinical studies were completed on time. Delays in the completion of postmarketing requirements often did not impact the likelihood of drugs receiving permanent marketing authorization (87%, 39/45) after 5 years. Our findings highlight the need for EMA to better enforce its authority to require timely completion of postmarketing requirements and studies.Keywords
Funding Information
- London School of Economics and Political Science
This publication has 17 references indexed in Scilit:
- Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13BMJ, 2017
- The Fate of FDA Postapproval StudiesNew England Journal of Medicine, 2017
- Post‐marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross‐sectional studyInternational Journal of Cancer, 2017
- Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort studyBMJ, 2017
- Characteristics of Preapproval and Postapproval Studies for Drugs Granted Accelerated Approval by the US Food and Drug AdministrationJAMA, 2017
- Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010JAMA, 2017
- Registries in European post‐marketing surveillance: a retrospective analysis of centrally approved products, 2005–2013Pharmacoepidemiology and Drug Safety, 2017
- Characteristics and follow‐up of postmarketing studies of conditionally authorized medicines in the EUBritish Journal of Clinical Pharmacology, 2016
- Approvals of drugs with uncertain benefit–risk profiles in EuropeEuropean Journal of Internal Medicine, 2015
- An investigation into drug products withdrawn from the EU market between 2002 and 2011 for safety reasons and the evidence used to support the decision-makingBMJ Open, 2014